Germany research report

Germany: research and access context

Editorial sources checked 9 October 2026. Registry facts refresh separately; the latest indexed registry check is Oct 30, 2026 02:24 UTC. This report covers psilocybin and psilocin, not the entire psychedelic sector.

Access, payment and evidence are separate questions

The BfArM procedure and AMHV concern cohort programmes, not individual named-patient applications. Current entry criteria and capacity must be checked with the responsible programme. A registry recruitment flag does not establish personal eligibility.

The G-BA explanation of AMNOG describes added-benefit assessment and its role in reimbursement pricing. It does not establish a psilocybin reimbursement decision. This report does not assert routine insurance coverage, a treatment price, or a regulatory approval forecast.

Explore registry geography and organisations

3 trials match this view; 139 reported facilities; 139 have usable coordinates. Latest indexed registry check Oct 30, 2026 02:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 949 across 3 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Matching trial records

Reported research facilities

This directory includes reported facilities with and without coordinates. For a country-filtered view, locations are labeled as selected-country sites or international sites of matching trials. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.